Cite this: Org. Biomol. Chem., 2012, 10, 8164

PAPER

Organocatalytic asymmetric syntheses of inthomycins A, B and C†

Madoka Yoshino, Kohei Eto, Keisuke Takahashi, Jun Ishihara and Susumi Hatakeyama*

Received 5th June 2012, Accepted 29th August 2012 DOI: 10.1039/c2ob26084k

The total syntheses of (+)-inthomycin A, (+)-inthomycin B and (–)-inthomycin C, the oxazole-triene antibiotics isolated from *Streptomyces* sp., have been accomplished *via* the highly enantio- and stereoselective construction of the C1–C7 (iododienyl)aldol units by taking advantage of a *Cinchona* alkaloid-catalyzed asymmetric β -lactone synthesis and their isomerisation-free Stille coupling with (*E*)-5-(3-(tributylstannyl)allyl)oxazole.

Introduction

Since Uemura and co-workers first reported the isolation of oxazolomycin A and neooxazolomycin in 1985,¹ many congeners containing a methylene-interrupted oxazolyl-triene motif and a spiro fused β -lactone/ γ -lactam core have been isolated from strains of Streptomyces sp. (Fig. 1).² These antibiotics exhibit wide ranging and potent antibacterial and antiviral activities as well as in vivo antitumor activity.² Due to such intriguing biological properties and characteristic structures, a number of efforts have been dedicated towards the synthesis of the oxazolomycin family of antibiotics.^{2,3} However, Kende's total synthesis⁴ of neooxazolomycin had long been the only achievement until we recently reported the syntheses of neooxazolomycin⁵ and oxazolomycin A.⁶ In order to synthesize other members of this family, we need to develop an efficient methodology which allows us to secure the left hand segments having $4'Z_{,6}'Z_{,8}'E_{-,8}$ 4'E,6'E,8'E- and 4'Z,6'E,8'E-triene systems stereoselectively. Under this situation, we became interested in the synthesis of inthomycins A, B and C which have the structures corresponding to the left hand segments of the oxazolomycins.

In 1990, Ōmura *et al.* isolated phthoxazolin A from the strain of *Streptomyces* sp. OM-5714.⁷ Then, the following year, Henkel and Zeek⁸ discovered inthomycin A together with the geometrical isomers inthomycins B and C from the strain of *Streptomyces* sp. Gö 2, and proved inthomycin A to be identical with phthoxazolin A. These inthomycins are found to be highly specific inhibitors of cellulose biosynthesis, displaying significant antimicrobial⁹ and herbicidal activities.¹⁰ In addition, inthomycin A was also shown to strongly inhibit the growth of

E-mail: susumi@nagasaki-u.ac.jp; Fax: +81-95-819-2426;

⁺Electronic supplementary information (ESI) available: ¹H NMR and ¹³C NMR spectra for all isolated intermediates and inthomycins A, B and C. See DOI: 10.1039/c2ob26084k



Fig. 1 The oxazolomycins and the inthomycins.

prostate cancer cells.¹¹ Although the syntheses of (\pm) -inthomycin A,¹² (+)-inthomycin B^{12c,13} and (-)-inthomycin C¹⁴ have

Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-Machi, Nagasaki 852-8521, Japan.

Tel: +81-95-819-2426



already been accomplished, there is no report of the asymmetric synthesis of all of these three compounds based on an unified methodology which enables us to secure the left-hand segments of most members of the oxazolomycin family. Herein, we report the highly enantio- and stereocontrolled total syntheses of (+)-inthomycin A, (+)-inthomycin B and (-)-inthomycin C starting with an organocatalytic asymmetric [2+2] cycloaddition reaction of an aldehyde and a ketene.¹⁵

Results and discussion

Scheme 1 illustrates our retrosynthetic analysis of inthomycins A, B and C. The disconnection of the C7–C8 bond by a Stille coupling gives us (E)-5-(3-(tributylstannyl)allyl)oxazole (1)^{12c} and three iododienes Z,Z-2, Z,E-3 and E,E-4. We assumed that each of these iododienes could be prepared regio- and stereoselectively via either iodination-semihydrogenation or hydrometallation-iodination from alkyne 5 or alkyne 6. To expeditiously access 5 and 6 we envisioned organocatalytic asymmetric synthesis of β -lactones 7 and 8 from aldehydes 9 and 10 as a starting point. Although such a chiral amine-catalyzed [2+2] cycloaddition reaction involving an aldol-lactonization process has been well established by Romo et al.,¹⁶ Fu et al.,¹⁷ and Nelson et al.,¹⁸ the reaction of a conjugated aldehyde such as 9 has rarely been examined to-date.[‡] This strategy is therefore challenging, and an enantioselectivity issue of the key β-lactone formations is of great interest.

The required Z-aldehyde **9** and E-aldehyde **10** were prepared from propargyl alcohol in geometrically pure forms (Scheme 2). Thus, according to the procedure we previously established, 5^{a}



TMSQD: quinidine TMS ether

Scheme 3 Unsuccessful asymmetric [2+2] cycloadditions.

Z-aldehyde **9** was synthesized by a three-step sequence involving copper-catalyzed addition of methylmagnesium bromide followed by iodination,^{12*a*} Sonogashira coupling of **11** with ethy-nyltrimethylsilane, and MnO₂ oxidation of **12**. Similarly, *E*-aldehyde **10** was obtained *via* Negishi methylation-iodination,¹⁹ Sonogashira coupling of **13** with ethynyltrimethylsilane, and MnO₂ oxidation of **14**.

We first examined the reaction of **9** and dimethylketene, generated by Zn-mediated reduction of 2-bromo-2-methylpropanoyl bromide, using **15** as a catalyst under Fu's conditions;¹⁷ however, the desired β -lactone **7** was not produced at all (Scheme 3).

[‡]Several successful reactions using simple ynals have been reported.^{18a,b}



 a Isolated yield. b Determined by chiral HPLC analysis. c The enantiomer of ${\bf 16}$ was obtained.

We then investigated the *Cinchona* alkaloid-catalyzed reaction of **9** with isobutyryl chloride according to Nelson's procedure¹⁸ using quinidine TMS ether (TMSQD), LiClO₄ and Hünig's base. This method again did not give us any encouraging results. Alternatively, we also explored the reaction of **9** with dimethylketene under the TMSQD/LiClO₄-catalyzed conditions. In this case, the desired β-lactone **7** was obtained but the yield and the enantioselectivity were disappointingly low. These results suggested that the gem-dimethyl groups of the ketene hampered this reaction, possibly because of steric hindrance. Therefore, we alternatively planned to introduce one methyl group after an asymmetric cycloaddition reaction using propionyl chloride instead of isobutyryl chloride.

Table 1 illustrates the results obtained from the chiral aminecatalyzed reaction of Z-aldehyde 9 and propionyl chloride. When 9 was reacted with 2 equiv of propionyl chloride using 2 equiv of LiClO₄ and 10 mol% of TMSQD in CH₂Cl₂-Et₂O (2:1) at -78 °C, asymmetric cycloaddition proceeded with high enantio- and diastereoselectivity to give β -lactone 16 although the yield was very low (entry 1). We then gratifyingly found that when the amount of LiClO₄ was increased from 2 equiv to 4 equiv, the yield was dramatically improved and both ee and de values were again very high (entry 2). When 4 equiv of LiClO₄ and 20 mol% of TMSOD were used, the best result was obtained and β -lactone 16 was produced in 92% yield, 98% ee and 99% de (entry 3). Similarly, when quinine TMS ether (TMSQN) was employed as a catalyst, the corresponding enantiomer of 16 was obtained in high yield and excellent enantio- and diastereoselectivities. In addition, this method can be also applied to E-aldehyde 10, and β -lactone 17 was produced again in high yield and excellent enantio- and diastereoselectivities (Scheme 4). The stereostructure of 16 was confirmed by its NOESY spectrum and the absolute configuration was determined by its conversion to the known ester 5.5^{56}

Synthesis of (+)-inthomycin A

The synthesis of (+)-inthomycin A began with the preparation of Z,Z-iododiene **2** from β -lactone **16** (Scheme 5). Thus, methanolysis of **16** gave methyl ester **18** which was methylated according



Scheme 4 TMSQD-catalyzed reaction of 10 with propionyl chloride.



Scheme 5 Preparation of Z,Z-iododiene 2.

to Seebach's protocol²⁰ to afford hydroxy ester **19** in good yield. Desilylation of **19** followed by TBS protection of **20** gave the known ester **5** which was stereoselectively converted to Z,Z-iododiene **2** following the previously established procedure^{5a} involving an iodination and a diimide reduction.

According to Baldwin's method, 12c,21 compound **2** was then subjected to Stille coupling with stannane **1** using Pd(PPh₃)₄, CuI and CsF in DMF at room temperature to give *Z*,*Z*,*E*-triene **21** in geometrically pure form (Scheme 6). When this coupling was carried out using Pd(0) catalyst alone, some extent of isomerization of the triene system was always observed.²¹ After desilylation of **21**, compound **22** was successively subjected to saponification, acetylation, and amidation to give acetate **23**. Finally, removal of the acetyl group of **23** completed the first total synthesis of (+)-inthomycin A. The spectroscopic data and specific rotation were identical with those reported^{7a,12c} for natural inthomycin A.

Synthesis of (+)-inthomycin B

For the synthesis of inthomycin B, *Z*,*E*-iododiene **3** was first synthesized from **5** by hydrozirconation²² followed by iodination (Scheme 7). Thus, alkyne **5** was treated with *in situ* prepared



Scheme 6 Synthesis of (+)-inthomycin A.



Scheme 7 Synthesis of (+)-inthomycin B.

Schwartz's reagent from zirconocene dichloride and DIBAL followed by iodine to produce an inseparable 6 : 1 mixture of *Z*,*E*iododiene **3** and its 6-iodo-isomer in 82% yield. The mixture was then subjected to Stille coupling with **1** under the same conditions mentioned for the coupling of **2** and **1** to give *Z*,*E*,*E*triene **24** stereoselectively in moderate yield. From coupling product **24**, (+)-inthomycin B was successfully synthesized *via* a



Scheme 8 Preparation of E,E-iododiene 4.

five step-sequence involving desilylation, hydrolysis, acetylation, amidation and removal of the acetyl group. The spectroscopic data were in accord with those reported^{12c} for natural inthomycin B.

Synthesis of (-)-inthomycin C

E-Alkyne **6** was prepared from β -lactone **17** in 80% overall yield in the same manner as described for the synthesis of **5** from **16** (Scheme 8). *E*-Alkyne **6** was then subjected to hydrozirconation followed by iodination but the transformation proceeded with poor regioselectivity to afford a 2 : 1 mixture of **4** and its 6-iodoisomer in 61% yield. We then examined the hydrostannylation²³ and hydrosilylation²⁴ of **6** under various conditions. However, as seen in Table 2, these methods did not exhibit high regioselectivity although the yields were satisfying in all cases.

After considerable experimentation, we eventually found that a stannylcupration-iodination^{23*a*} converted **26** to *E*,*E*-iododiene **29** with high regioselectivity (Scheme 9). Thus, when **26** was treated with Bu₃Sn(Bu)CuCNLi₂ in THF at -78 °C followed by iodine, a 7 : 1 mixture of **29** and its 6-iodo-isomer was obtained in 60% yield. Stille coupling of **29** with **1** using Pd(PPh₃)₄, CuI, and CsF in DMF proceeded at room temperature without isomerisation and geometrically pure *E*,*E*,*E*-triene **30** was produced in 83% yield. From coupling product **30**, the total synthesis of (–)-inthomycin C was accomplished *via* a four-step sequence involving hydrolysis, acetylation, amidation and removal of the acetyl group. The spectroscopic data§ and specific rotation were identical with those reported^{12c,14} for natural inthomycin C.

Conclusions

We have achieved highly enantio- and stereoselective syntheses of inthomycins A, B and C in naturally occurring forms starting with a *Cinchona* alkaloid-catalyzed asymmetric [2+2] cycloaddition of an aldehyde and a ketene. The present methodology

[§] Taylor *et al.* reported^{12c} that inthomycin C showed $[\alpha]_D^{21}$ +25.9 (*c* 0.27, CHCl₃). Recently, Ryu *et al.* reported¹⁴ it to be $[\alpha]_D^{20}$ -34.3 (*c* 0.10, CHCl₃) which is close to our observation ($[\alpha]_D^{23}$ -41.5 (*c* 0.10, CHCl₃)).

Table 2Hydrometallations of alkyne 6



Entry	М	Conditions	Yield ^a (%)	27 : 28 ^b
1	Bu ₃ Sn	Bu ₃ SnH (1.5 eq), AIBN (5 mol%), benzene (0.1 M), reflux, 2.5 h	91	1:1
2	Bu ₃ Sn	$PdCl_2(PPh_3)_2$ (20 mol%), Bu_3SnH (1.5 eq), THF (0.1 M), rt	80	2:5
3	Bu ₃ Sn	$Pd_2(dba)_3$ (0.5 mol%), Bu ₃ SnH (1.2 eq), Cv_3PHBF_4 (2 mol%), ${}^{i}Pr_2NEt$, toluene (0.04 M), rt, 30 min	67	1.1:1
4	Bu ₃ Sn	Pd ₂ (dba) ₃ (0.5 mol%), Bu ₃ SnH (1.2 eq), Cy ₃ PHBF ₄ (2 mol%), ⁱ Pr ₂ NEt, toluene (0.04 M), 0 °C, 30 min	73	4:1
5^c	(EtO) ₃ Si	(EtO) ₃ SiH (3 eq), Pt(dvds) (3 mol%), CH ₂ Cl ₂ (0.05 M), 0 °C to rt	82	1.3:1
6 ^{<i>c</i>}	(EtO) ₃ Si	$(EtO)_{3}SiH (3 eq), Pt(dvds) (3 mol%), CH_{2}Cl_{2} (0.05 M), -78 to -40 °C$	80	1.1:1

^a Isolated yield. ^b Determined by ¹H NMR analysis. ^c Pt(dvds) = platinum(0)-1,3-divinyl-1,1,3,3-tetramethyldisiloxane complex



Scheme 9 Synthesis of (–)-inthomycin C.

is of general value in approaches to the related oxazolomycins, the syntheses of which are currently under investigation.

Experimental section

General

Where appropriate, reactions were performed in flame-dried glassware under argon atmosphere. All extracts were dried over

MgSO₄ and concentrated by rotary evaporation below 30 °C at 25 Torr unless otherwise noted. Commercial reagents and solvents were used as supplied with the following exceptions. N.N-Dimethylformamide (DMF), dichloromethane (CH₂Cl₂), acetonitrile (MeCN), benzene and toluene were distilled from CaH₂. Methanol (MeOH) was distilled from sodium. Thin-layer chromatography (TLC) was performed using precoated silica gel plates (0.2 or 0.5 mm thickness). Column chromatography was performed using silica gel (particle size: 100-210 µm (regular), 40-50 um (flash)). Optical rotations were recorded on a digital polarimeter at ambient temperature. Infrared spectra were measured on a Fourier transform infrared spectrometer. ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) spectra were measured using CDCl₃ as solvent, and chemical shifts are reported as δ values in ppm based on internal CHCl₃ (7.26 ppm, ¹H; 77.0 ppm, ¹³C). Mass spectra (MS and HRMS) were taken in EI mode.

(Z)-3-Iodo-2-methylprop-2-en-1-ol (11). To a suspension of propargyl alcohol (2.0 g, 35.6 mmol) and CuI (6.78 g, 35.6 mmol) in Et₂O (100 mL) was added MeMgBr (1.65 M in Et₂O, 45 mL, 74.8 mmol) at -5 °C. The mixture was gradually allowed to warm to room temperature and stirred for additional 2 h. ICl (5.78 g, 35.6 mmol) was then added at -5 °C, and the mixture was allowed to warm to room temperature and stirring was continued for 16 h. The mixture was diluted with saturated NH₄Cl (50 mL) at 0 °C and filtered through Celite[®]. The filtrate was extracted with Et₂O, washed with brine, dried and concentrated. Purification of the residue by column chromatography $(SiO_2 \ 150 \ g, hexane-AcOEt = 5:1)$ gave 11^{12b} (4.60 g, 65%) as a pale yellow oil. ¹H NMR δ 5.99 (s, 1H), 4.25 (s, 2H), 1.98 (s, 3H); ¹³C NMR δ 146.1, 74.9, 68.1, 21.6; FTIR (neat) 3419, 2911, 2187, 2012, 1618, 1283, 1137, 1046 cm⁻¹; HRMS calcd for C₄H₇OI (M⁺) 197.9541; found 197.9515.

(Z)-2-Methyl-5-(trimethylsilyl)pent-2-en-4-yn-1-ol (12). To a solution of 11 (4.0 g, 20.2 mmol) in degassed THF (102 mL)

were added ethynyltrimethylsilane (5.6 mL, 40.8 mmol), diisopropylamine (24 mL, 153.7 mmol), PdCl₂(PPh₃)₂ (288.2 mg, 0.4 mmol) and CuI (272 mg, 1.6 mmol) at room temperature. After being stirred at room temperature for 1 h under sonication, the mixture was diluted with saturated NaHCO₃ (200 mL), extracted with Et₂O, washed with brine, dried and concentrated. Purification of the residue by column chromatography (SiO₂ 180 g, hexane–AcOEt = 10 : 1 to 5 : 1) gave **12** (3.46 g, 100%) as a reddish brown oil. ¹H NMR δ 5.41 (s, 1H), 4.36 (d, *J* = 6.4 Hz, 2H), 1.88 (s, 3H), 0.19 (s, 9H); ¹³C NMR δ 151.9, 106.7, 101.6, 64.1, 20.3; FTIR (neat) 3393, 2143, 1629, 1448, 1254, 1100 cm⁻¹; HRMS calcd for C₉H₁₆OSi (M⁺) 168.0970, found 168.0964.

(*Z*)-2-Methyl-5-(trimethylsilyl)pent-2-en-4-ynal (9). To a suspension of activated MnO₂ (14.4 g, 177 mmol) in hexane–CH₂Cl₂ (3:2) (50 mL) was added a solution of **12** (2.0 g, 11.8 mmol) in CH₂Cl₂ (10 mL) at room temperature. The mixture was stirred at room temperature for 24 h and filtered through Celite[®] which was washed with Et₂O. The combined filtrate and washings were concentrated and the residue was purified by column chromatography (SiO₂ 100 g, hexane–AcOEt = 100:1) to give **9** (1.80 g, 92%) as a brown oil. ¹H NMR δ 10.25 (s, 1H), 6.53 (s, 1H), 1.86 (s, 3H), 0.22 (s, 9H); ¹³C NMR δ 192.5, 147.4, 125.8, 106.5, 92.3, 15.5, 0.3; FTIR (neat) 3557, 3357, 2138, 1697, 1257, 1100 cm⁻¹; MS *m*/*z* 57, 131, 151 (100), 166 (M⁺); HRMS calcd for C₉H₁₄OSi (M⁺) 166.0814, found 166.0800.

(E)-3-Iodo-2-methylprop-2-en-1-ol (13). To a solution of Me₃Al (2.0 M in hexane, 78 mL, 156 mmol) and Cp₂ZrCl₂ (18.2 g, 62.4 mmol) in CH₂Cl₂ (80 mL) was added propargyl alcohol (3.5 g, 62.4 mmol) at 0 °C, and the mixture was stirred at room temperature for 14 h. A solution of I2 (2.08 g, 8.21 mmol) in THF (5.0 mL) was added at -78 °C, and the mixture was allowed to warm to room temperature. After being stirred at room temperature for 1 h, the mixture was acidified with 3 M HCl at 0 °C, extracted with AcOEt, washed with saturated NaHCO₃, saturated Na₂S₂O₃ and brine, dried and concentrated. Purification of the residue by column chromatography $(SiO_2 250 \text{ g}, \text{hexane}-\text{AcOEt} = 3:1)$ gave 13 (6.82 g, 55%) as a yellow oil. ¹H NMR δ 6.29 (s, 1H), 4.13 (d, J = 5.9 Hz, 2H), 1.85 (s, 3H); ¹³C NMR δ 147.1, 77.3, 66.7, 21.3; FTIR (neat) 3316, 2914, 1624, 1274, 1012 cm⁻¹; MS *m/z* 71, 198 (100, M⁺); HRMS calcd for C₄H₇OI (M⁺) 197.9542, found 197.9536.

(*E*)-2-Methyl-5-(trimethylsilyl)pent-2-en-4-yn-1-ol (14). Iodide 13 (1.82 g, 9.19 mmol) was subjected to Sonogashira coupling using ethynyltrimethylsilane (2.6 mL, 18.4 mmol), diisopropylamine (9.4 mL, 68.9 mmol), PdCl₂(PPh₃)₂ (110 mg, 0.18 mmol), and CuI (110 mg, 0.64 mmol) in the same manner as described for the preparation of 12 from 11. Purification by column chromatography (SiO₂ 80 g, hexane–AcOEt = 7 : 1 to 5 : 1) afforded 14 (1.53 g, 99%) as a reddish brown oil. ¹H NMR δ 5.61 (s, 1H), 4.12 (d, *J* = 6.3 Hz, 2H), 1.91 (s, 3H), 0.20 (s, 9H); ¹³C NMR δ 151.6, 104.6, 102.4, 98.4, 66.7, 16.5, 0.0; FTIR (neat) 3329, 2138, 1252, 1098 cm⁻¹; MS *m/z* 153 (100) 168 (M⁺); HRMS calcd for C₉H₁₆OSi (M⁺) 168.0970, found 168.0961. (*E*)-2-Methyl-5-(trimethylsilyl)pent-2-en-4-ynal (10). Alcohol 14 (2.5 g, 14.9 mmol) was oxidized using activated MnO₂ (12.9 g, 149 mmol) in the same manner as described for the preparation of 9 from 12. Purification by column chromatography (SiO₂ 120 g, hexane–AcOEt = 80 : 1) gave 10 (2.32 g, 94%) as a brown oil. ¹H NMR δ 9.46 (s, 1H), 6.33 (s, 1H), 1.94 (s, 3H), 0.24 (s, 9H); ¹³C NMR δ 194.1, 149.0, 128.6, 113.8, 100.1, 11.8, -0.4; FTIR (neat) 2961, 2821, 2713, 2137, 1689, 1604, 1092 cm⁻¹; MS *m/z* 43, 151, 166 (100, M⁺); HRMS calcd for C₉H₁₄OSi (M⁺) 166.0814, found 166.0784.

(3S,4S)-3-Methyl-4-((Z)-5-(trimethylsilyl)pent-2-en-4-yn-2-yl)oxetan-2-one (16). To a solution of LiClO₄ (1.28 g, 12.0 mmol) and TMSQD¹⁸ (240 mg, 0.60 mmol) in CH₂Cl₂-hexane (1:1) (10 mL) were added a solution of 9 (500 mg, 3.0 mmol) in CH₂Cl₂ (2.5 mL) and diisopropylethylamine (1.32 mL, 7.50 mmol) at -78 °C. A solution of propionyl chloride (0.50 mL, 6.0 mmol) in CH₂Cl₂ (2.0 mL) was then added slowly over 2 h. After being stirred at -78 °C for 20 h, the mixture was diluted with Et₂O (50 mL) and filtered through a short silica gel column. The filtrate was concentrated and chromatographed (SiO₂ 50 g, hexane-AcOEt = 80:1 to 20:1) to give 16 (0.61 g, 92%) as a yellow oil. $[\alpha]_{D}^{20}$ -267.3 (c 0.92, CHCl₃); ¹H NMR δ 5.57 (s, 1H), 5.52 (d, J = 6.8 Hz, 1H), 3.94 (qd, J = 7.8, 6.8 Hz, 1H), 1.87 (s, 3H), 1.18 (d, J = 7.8 Hz, 3H), 0.19 (s, 9H); ¹³C NMR δ 171.8, 147.0, 108.6, 101.3, 100.3, 74.9, 50.0, 19.5, 8.8, -0.3; FTIR (neat) 2138, 1836, 1763, 1446, 1253, 1102 cm⁻¹; MS m/z 57 (100), 151, 222 (M⁺); HRMS calcd for C12H18O2Si (M⁺) 222.1076, found 222.1096. The enantiomeric excess and diastereomeric excess were determined to be 98% ee and >99% de by chiral HPLC analysis: Daicel Chiralcel AS, 2-propanol-hexane = $1:800 (0.5 \text{ mL min}^{-1})$, $t_{\rm R} = 20.2 \min(S,S)$ and 25.2 min (*R*,*R*).

(3*R*,4*R*)-3-Methyl-4-((*Z*)-5-(trimethylsilyl)pent-2-en-4-yn-2-yl)oxetan-2-one. The reaction of **9** (50 mg, 0.30 mmol) and propionyl chloride (50 µL, 0.60 mmol) was carried out using LiClO₄ (1.28 g, 12.0 mmol), TMSQN¹⁸ (0.24 mg, 0.60 mmol) and diisopropylethylamine (0.13 ml, 0.75 mmol) at -78 °C for 20 h in the same manner as described for the preparation of **16** from **9**. Purification by column chromatography (SiO₂ 6.0 g, hexane– AcOEt = 80 : 1 to 10 : 1) to give the title compound (56 mg, 84%), an enantiomer of **16**, as a yellow oil. $[\alpha]_D^{20}$ +262.9 (*c* 0.88, CHCl₃). The enantiomeric excess and diastereomeric excess were determined to be 97% ee and >99% de by chiral HPLC analysis: Daicel Chiralcel AD, 2-propanol–hexane = 1 : 800 (0.7 mL min⁻¹), $t_R = 21.5$ min (*R*,*R*) and 32.9 min (*S*,*S*).

(35,45)-3-Methyl-4-((*E*)-5-(trimethylsilyl)-pent-2-en-4-yn-2-yl)oxetan-2-one (17). The reaction of 10 (2.12 g, 12.7 mmol) with propionyl chloride (2.22 mL, 25.4 mmol) was carried out using LiClO₄ (5.40 g, 50.8 mmol), TMSQD (1.0 g, 2.54 mmol) and diisopropylethylamine (5.54 mL, 50.8 mmol) in the same manner as described for the preparation of 16 from 9. Purification by column chromatography (SiO₂ 120 g, hexane–AcOEt = 80 : 1 to 20 : 1) gave 17 (2.39 g, 85%) as a yellow oil. $[\alpha]_D^{22}$ -123.9 (*c* 1.02, CHCl₃); ¹H NMR δ 5.73 (s, 1H), 4.98 (d, *J* = 6.4 Hz, 1H), 3.91 (qd, *J* = 7.5, 6.4 Hz, 1H), 1.89 (s, 3H), 1.21 (d, *J* = 7.5 Hz, 3H), 0.21 (s, 9H); ¹³C NMR δ 171.1, 144.3, 107.9, 100.9, 100.7, 75.7, 49.7, 16.4, 8.7, -0.1; FTIR (neat) 2961, 2137, 1839, 1254, 1104 cm⁻¹; MS m/z 43 (100), 163, 222 (M⁺); HRMS calcd for C₁₂H₁₈O₂Si (M⁺) 222.1076, found 222.1091.

(2*S*,3*S*,*Z*)-Methyl 3-hydroxy-2,4-dimethyl-7-(trimethylsilyl)hept-4-en-6-ynoate (18). To a solution of 16 (2.49 g, 11.2 mmol) in MeOH (110 mL) was added NaOMe (6.0 mg, 0.112 mmol) at 0 °C. After being stirred at room temperature for 30 min, the mixture was diluted with saturated NH₄Cl (50 mL), concentrated, and extracted with AcOEt. The extract was washed with brine concentrated and chromatographed (SiO₂ 80 g, hexane-AcOEt = 8:1) to give **18** (2.71 g, 95%) as a yellow oil. $[\alpha]_{D}^{24}$ -58.2 (c 1.02, CHCl₃); ¹H NMR δ 5.41 (s, 1H), 5.02 (d, J = 4.6 Hz, 1H), 3.70 (s, 3H), 2.95 (dq, J = 4.6, 7.1 Hz,, 1H), 2.80 (brs, 1H), 1.84 (s, 3H), 1.22 (d, J = 7.1 Hz, 3H), 0.18 (s, 9H); ¹³C NMR δ 175.5, 153.5, 106.5, 101.4, 100.1, 72.8, 51.8, 43.9, 19.1, 11.4, -0.2; FTIR (neat) 3495, 2136, 1730, 1445, 1254, 1201, 1093, 1032 cm⁻¹; MS m/z 73, 167 (100), 254 (M⁺); HRMS calcd for $C_{13}H_{22}O_3Si(M^+)$ 254.1338, found 254.1329.

(R,Z)-Methyl 3-hydroxy-2,2,4-trimethyl-7-(trimethylsilyl)hept-4-en-6-ynoate (19). To a solution of diisopropylamine (3.9 mL, 27.7 mmol) in THF (40 mL) was added dropwise n-BuLi (2.67 M in hexane, 8.8 mL, 24.4 mmol) at -78 °C. After stirring at -78 °C for 45 min, a solution of 18 (1.68 g, 6.60 mmol) in THF (10 mL) was added, and the mixture was allowed to warm to -20 °C and stirring was continued for 20 min. Iodomethane (4.1 mL, 66.0 mmol) was then added at -78 °C, and the mixture was allowed to warm to -20 °C. After stirring at -20 °C for 4 h. the reaction was quenched with saturated NH₄Cl (50 mL), and the mixture was extracted with AcOEt. The extract was washed with brine, concentrated and purified by flash column chromatography (SiO₂ 60 g, CHCl₃-hexane = 4:1) to give **19** (1.48 g, 84%) as a yellow oil. $[\alpha]_{\rm D}^{24}$ -32.7 (c 1.24, CHCl₃); ¹H NMR δ 5.48 (s, 1H), 4.90 (d, J = 7.3 Hz, 1H), 3.72 (s, 3H), 3.49 (d, J = 7.3 Hz, 1H), 1.73 (s, 3H), 1.34 (s, 3H), 1.20 (s, 3H), 0.18 (s, 9H); ¹³C NMR δ 178.2, 151.0, 110.0, 102.3, 99.3, 77.2, 52.1, 46.9, 24.5, 20.5, 18.3, -0.2; FTIR (neat) 3506, 2132, 1727, 1464, 1260, 1137, 1045 cm⁻¹; MS m/z 139, 151 (100), 168, 181, 195, 268 (M^+); HRMS calcd for $C_{14}H_{24}O_3Si$ (M^+) 268.1495, found 268.1500.

(*R*,*Z*)-Methyl 3-hydroxy-2,2,4-trimethylhept-4-en-6-ynoate (20). To a solution of 19 (129 mg, 0.48 mmol) in MeOH (5.0 mL) was added NaOMe (13 mg, 0.24 mmol) at 0 °C. After being stirred at room temperature for 4 h, the mixture was diluted with saturated NH₄Cl (10 mL), extracted with AcOEt, washed with brine and concentrated. Purification of the residue by column chromatography (SiO₂ 5.0 g, hexane–AcOEt = 6 : 1) gave 20 (92 mg, 98%) as a yellow oil. $[\alpha]_D^{24}$ –18.0 (*c* 1.20, CHCl₃); ¹H NMR δ 5.47 (s, 1H), 4.87 (d, *J* = 7.5 Hz, 1H), 3.73 (s, 3H), 1.20 (s, 3H); ¹³C NMR δ 178.1, 151.2, 108.5, 81.7, 80.3, 58.2, 52.0, 46.3, 24.3, 20.4, 18.0; FTIR (neat) 3474, 3290, 2371, 2096, 1719, 1441, 1263, 1049 cm⁻¹; HRMS calcd for C₁₁H₁₆O₃ (M⁺) 196.1099, found 196.1092.

(*R*,*Z*)-Methyl 3-(*tert*-buthyldimethylsilyloxy)-2,2,4-trimethylhept-4-en-6-ynoate (5). To a solution of 20 (600 mg, 3.1 mmol) in CH_2Cl_2 (13 mL) were added 2,6-lutidine (1.4 mL, 12.4 mmol) and TBSOTf (2.7 mL, 7.9 mmol) at 0 °C. The mixture was allowed to warm to room temperature and stirring was continued for 0.5 h. The mixture was diluted with saturated NH₄Cl (10 mL) at 0 °C and extracted with AcOEt. The extract was washed with brine, dried, concentrated and chromatographed (SiO₂ 30 g, hexane–AcOEt = 100:1) to give 5^4 (900 mg, 100%) as a colorless oil. $[\alpha]_{D^2}^{D^2}$ +115.3 (*c* 1.1, CH₂Cl₂); ¹H NMR δ 5.44 (s, 1H), 5.15 (s, 1H), 3.66 (s, 3H), 3.13 (d, *J* = 1.5 Hz, 1H), 1.80 (s, 3H), 1.21 (s, 3H), 1.18 (s, 3H), 0.87 (s, 9H), 0.06 (s, 3H), -0.02 (s, 3H); ¹³C NMR δ 177.2, 153.1, 108.8, 82.2, 80.9, 52.0, 49.4, 25.9, 22.9, 21.0, 18.9, 18.3, -4.6, -5.3; FTIR (neat) 3311, 1735, 1468, 1256, 1136, 1083 cm⁻¹; HRMS calcd for C₁₇H₃₀O₃Si (M⁺) 310.1965, found 310.1938.

(R,Z)-Methyl 3-((tert-butyldimethylsilyl)oxy)-7-iodo-2,2,4-trimethylhept-4-en-6-ynoate. To a solution of 5 (600 mg, 1.94 mmol) in THF (10 mL) was added dropwise n-BuLi (1.6 M in hexane, 1.34 mL, 2.14 mmol) at -78 °C. After stirring at -78 °C for 1 h, a solution of I₂ (984 mg, 3.88 mmol) in THF (2.0 mL) was added and stirring was continued at -78 °C for 1 h. The mixture was allowed to warm to 0 °C and saturated Na₂S₂O₃ (10 mL) was added. The mixture was extracted with AcOEt, washed with brine, dried, concentrated and chromatographed (SiO₂ 50 g, hexane–AcOEt = 7:1) to give the corresponding iodide⁴ (841 mg, 99%) as a pale yellow oil. $\left[\alpha\right]_{D}^{23}$ +93.4 (c 1.0, CH₂Cl₂); ¹H NMR δ 5.55 (s, 1H), 5.10 (s, 1H), 3.67 (s, 3H), 1.80 (s, 3H), 1.20 (s, 3H), 1.16 (s, 3H), 0.88 (s, 9H), 0.06 (s, 3H), -0.03 (s, 3H); ¹³C NMR δ 176.7, 154.0, 109.6, 91.4, 76.5, 51.8, 49.0, 25.7, 22.4, 20.9, 18.4, 18.0, -4.9, -5.6; FTIR (neat) 1736, 1468, 1388, 1255, 1137, 1079, 1000 cm⁻¹; HRMS calcd for $C_{17}H_{29}O_3SiI(M^+)$ 436.0931, found 436.0922.

(R,4Z,6Z)-Methyl 3-(tert-butyldimethylsilyloxy)-7-iodo-2,2,4trimethylhepta-4,6-dienoate (2). To a solution of the iodide (50 mg, 0.11 mmol) in THF-i-PrOH (1:1) (1.4 mL) were added triethylamine (0.024 mL, 0.17 mmol) and o-nitrobenzenesulfonyl hydrazide (40 mg, 0.18 mmol), and the mixture was stirred at room temperature. Triethylamine (0.012 mL, 0.085 mmol) and o-nitrobenzenesulfonyl hydrazide (20 mg, 0.090 mmol) were further added each 14 h later and 20 h later. After being stirred at room temperature for additional 6 h, the mixture was diluted with AcOEt, washed with H₂O and brine, dried and concentrated. Purification of the residue by flash column chromatography (SiO₂ 4.0 g, hexane–AcOEt = 10:1) gave 2^4 (48 mg, 100%) as a pale yellow oil. $[\alpha]_D^{23}$ +77.5 (c 1.35, CH₂Cl₂); ¹H NMR δ 7.00 (br, 1H), 6.25 (d, J = 6.3 Hz, 1H), 6.12 (d, J =10.3 Hz, 1H), 4.91 (brs, 1H), 3.63 (s, 3H), 1.84 (s, 3H), 1.23 (s, 3H), 1.10 (s, 3H), 0.88 (s, 9H), 0.02 (s, 3H), -0.04 (s, 3H); ¹³C NMR δ 176.8, 143.1, 133.2, 129.3, 83.0, 75.2, 51.8, 49.4, 25.6, 21.1, 18.0, -4.8, -5.6; FTIR (neat) 1741, 1469, 1386, 1260, 1091, 1012 cm⁻¹; HRMS calcd for C₁₇H₃₁O₃SiI (M⁺) 438.1087, found 438.1072.

(*R*,4*Z*,6*Z*,8*E*)-Methyl 3-((*tert*-butyldimethylsilyl)oxy)-2,2,4-trimethyl-10-(oxazol-5-yl)deca-4,6,8-trienoate (21). To a solution 2 (50 mg, 0.11 mmol) and stannane 1^{12c} (50 mg, 0.13 mmol) in degassed DMF (4.0 mL) were added CuI (2 mg, 0.011 mmol), CsF (35 mg, 0.23 mmol), and Pd(PPh₃)₄ (1 mg, 1.1 µmol) at room temperature. The mixture was stirred at room temperature for 5 h and concentrated. Purification of the residue by flash column chromatography (SiO₂ 8.0 g, hexane–AcOEt = 1 : 1 to 5 : 1) gave **21** (40 mg, 83%) as a pale yellow oil. $[\alpha]_D^{23}$ +123.1 (*c* 1.25, CH₂Cl₂); ¹H NMR δ 7.79 (s, 1H), 6.81 (s, 1H), 6.68 (dd, J = 11.2, 14.2 Hz, 1H), 6.41 (d, J = 12.0 Hz, 1H), 6.25 (dd, J = 11.0, 12.0 Hz, 1H), 5.95 (dd, J = 11.2, 11.0 Hz, 1H), 5.77 (td, J = 7.0, 14.2 Hz, 1H), 4.99 (brs, 1H), 3.62 (s, 3H), 3.52 (d, J = 7.0 Hz, 2H), 1.83 (s, 3H), 1.21 (s, 3H), 1.09 (s, 3H), 0.87 (s, 9H), 0.01 (s, 3H), -0.05 (s, 3H); ¹³C NMR δ 177.0, 150.7, 150.4, 139.0, 128.3, 127.5, 124.3, 124.1, 122.5, 73.7, 51.7, 49.4, 29.0, 25.6, 22.3, 21.2, 20.1, 18.0, -4.9, -5.6; FTIR (neat) 2950, 1732, 1508, 1465, 1255, 1078 cm⁻¹; MS *m*/*z* 173, 236, 318 (100), 362, 419 (M⁺); HRMS calcd for C₂₃H₃₇NO₄Si (M⁺) 419.2492, found 419.2493.

(R,4Z,6Z,8E)-Methyl 3-hydroxy-2,2,4-trimethyl-10-(oxazol-5yl)deca-4,6,8-trienoate (22). To a solution of 21 (210 mg, 0.51 mmol) in MeCN (10 mL) was added 47% HF (1.0 mL) at 0 °C, and the mixture was stirred at room temperature for 6 h. The mixture was basified with saturated NaHCO₃ (20 mL) at 0 °C and extracted with AcOEt. The extract was washed with brine, dried, concentrated and chromatographed (SiO₂ 10 g, hexane-AcOEt = 2:1) to give 22^4 (137 mg, 88%) as colorless needles; $[\alpha]_{\rm D}^{21}$ +100.6 (c 0.7, CH₂Cl₂); ¹H NMR δ 7.80 (s, 1H), 6.81 (s, 1H), 6.67 (dd, J = 11.7, 14.8 Hz, 1H), 6.44 (d, J = 11.7 Hz, 1H), 6.21 (dd, J = 11.1, 11.7 Hz, 1H), 5.96 (dd, J = 11.1, 11.7 Hz, 1H), 5.77 (td, J = 6.8, 14.8 Hz, 1H), 4.77 (d, J =6.8 Hz, 1H), 3.72 (s, 3H), 3.52 (d, J = 6.8 Hz, 2H), 3.33 (d, J = 6.8 Hz, 1H), 1.80 (s, 3H), 1.27 (s, 3H), 1.16 (s, 3H); $^{13}\mathrm{C}$ NMR δ 178.3, 150.7, 150.4, 137.7, 128.5, 128.2, 127.9, 124.9, 124.8, 122.5, 74.6, 52.2, 46.9, 29.0, 24.31, 21.0, 19.7; FTIR (neat) 3474, 2951, 2246, 1736, 1512, 1469, 1142 cm⁻¹; HRMS calcd for C₁₇H₂₃NO₄ (M⁺) 305.1627, found 305.1621.

(R,4Z,6Z,8E)-3-Acetoxy-2,2,4-trimethyl-10-(oxazol-5-yl)deca-4.6.8-trienoic acid. To a solution of 22 (60 mg, 0.196 mmol) in THF-MeOH-H₂O (3:1:1) (4.8 mL) was added LiOH (28 mg, 0.57 mmol) at 0 °C, and the mixture was stirred at room temperature for 24 h. The mixture was acidified with 1 M HCl at 0 °C and extracted with AcOEt. The extract was washed with brine, dried and concentrated to give the corresponding carboxylic acid (50 mg) as a yellow oil. The crude carboxylic acid (50 mg) was dissolved in pyridine (162 μ L) and Ac₂O (162 μ L, 1.70 mmol) was added at 0 °C. After stirring at room temperature for 20 h, a solution of NaHCO₃ (142 mg) in MeOH (1.0 mL) was added and stirring was continued for 1 h. The mixture was extracted with AcOEt, washed with brine, dried and concentrated. Purification of the residue by column chromatography (SiO₂ 2 g, $CHCl_3$ -MeOH = 1:19) gave the acetoxy acid⁴ (65 mg, 100%) as a yellow oil. ¹H NMR δ 7.80 (s, 1H), 6.82 (s, 1H), 6.63 (dd, J = 11.5, 14.4 Hz, 1H), 6.52 (d, J = 12.2 Hz, 1H), 6.36 (dd, J =11.0, 12.2 Hz, 1H), 6.01 (s, 1H), 5.98 (dd, J = 11.0, 11.5 Hz, 1H), 5.77 (td, J = 6.8, 14.4 Hz, 1H), 3.51 (d, J = 6.8 Hz, 2H), 2.05 (s, 3H), 1.82 (s, 3H), 1.26 (s, 3H), 1.22 (s, 3H); ¹³C NMR δ 180.4, 170, 150.8, 150.6, 133.2, 128.7, 128.6, 126.4, 124.3, 122.3, 75.8, 47.3, 29.0, 23.1, 21.0, 20.8, 20.7; FTIR (neat) 3528, 2923, 2532, 1749, 1512, 1471, 1370, 1271 cm⁻¹; HRMS calcd for C₁₈H₂₃NO₅ (M⁺) 333.1603, found 333.1573.

(*R*,4*Z*,6*Z*,8*E*)-2-Carbamoyl-2,4-dimethyl-10-(oxazol-5-yl)deca-4,6,8-trien-3-yl acetate (23). To a solution of the acetoxy acid (21 mg, 0.062 mmol) in CH₂Cl₂ (1.0 mL) were added SOCl₂ (7.0 µL, 0.10 mmol) and one drop of DMF at 0 °C. After stirring at room temperature for 2 h, 25% NH₄OH (2 mL) was added at 0 °C and the mixture was stirred at room temperature for 1 h. The mixture was diluted with H₂O (2.0 mL) and extracted with AcOEt. The extract was washed with brine, dried, concentrated and purified by flash column chromatography (SiO₂ 3.0 g, hexane-AcOEt = 9:1) to give 23 (12 mg, 58%) as a yellow oil. $[\alpha]_{D}^{24}$ +134.2 (c 0.84, CHCl₃); ¹H NMR δ 7.79 (s, 1H), 6.80 (s, 1H), 6.62 (dd, *J* = 11.7, 14.4 Hz, 1H), 6.49 (d, *J* = 11.7 Hz, 1H), 6.36 (dd, J = 11.0, 11.7 Hz, 1H), 6.04–5.98 (m, 2H), 5.86 (s, 1H), 5.79 (td, J = 6.8, 14.4 Hz, 1H), 5.86 (brs, 1H), 3.51 (d, J =6.8 Hz, 2H), 2.10 (s, 3H), 1.82 (s, 3H), 1.23 (s, 3H), 1.20 (s, 3H); 13 C NMR δ 178.2, 169.6, 151.0, 150.7, 133.4, 129.3, 128.5, 127.1, 124.2, 122.9, 46.5, 29.3, 25.1, 21.9, 21.2, 20.7; FTIR (neat) 3357, 3208, 2976, 2928, 1739, 1676, 1371, 1241, 1102, 1029 cm⁻¹; MS m/z 43, 204 (100), 332 (M^+) ; HRMS calcd for $C_{18}H_{24}N_2O_4$ (M⁺) 332.1736, found 332.1732.

(+)-Inthomycin A. To a solution of 23 (8.3 mg, 0.025 mmol) in THF-MeOH-H₂O (3:1:1) (1.5 mL) was added LiOH (2.0 mg, 0.05 mmol) at room temperature. After being stirred at room temperature for 1 h, the mixture was acidified with 1 M HCl at 0 °C and extracted with AcOEt. The extract was washed with brine, dried, concentrated and purified by preparative TLC $(CHCl_3-MeOH = 9:1)$ to give (+)-inthomycin A (6.2 mg, 86%) as a yellow oil. $[\alpha]_{D}^{21}$ +37.3 (c 0.62, CHCl₃) (lit.^{7a} $[\alpha]_{D}^{21}$ +37.4 (c 1.0, CHCl₃)); ¹H NMR δ 7.80 (s, 1H), 6.81 (s, 1H), 6.68 (dd, J = 11.5, 14.0 Hz, 1H), 6.42 (d, J = 11.7 Hz, 1H), 6.23–6.17 (m, 2H), 5.95 (dd, J = 11.0, 11.5 Hz, 1H), 5.78 (td, J = 6.4, 14.0 Hz, 1H), 5.54 (brs, 1H), 4.65 (s, 1H), 4.05 (s, 1H), 3.52 (d, J =6.4 Hz, 2H), 1.85 (s, 3H), 1.36 (s, 3H), 1.10 (s, 3H); 13 C NMR δ 181.0, 150.7, 150.4, 138.3, 128.7, 128.2, 124.9, 123.7, 122.5, 75.4, 44.6, 29.0, 26.1, 21.7, 19.4; FTIR (neat) 3341, 2926, 1658, 1510, 1468, 1263, 1109, 1039 cm⁻¹; MS m/z 87 (100), 290 (M^+) ; HRMS calcd for $C_{16}H_{22}N_2O_3$ (M^+) 290.1630, found 290.1629.

(R,4Z,6E)-Methyl 3-(tert-butyldimethylsilyloxy)-7-iodo-2,2,4trimethylhepta-4,6-dienoate (3). DIBAL (1.04 M in hexane; 7.7 mL, 8.05 mmol) was placed into a 100 mL flask and most of the hexane was evaporated. The residual DIBAL was dissolved in THF (5.0 mL) and added dropwise to a solution of Cp₂ZrCl₂ (2.35 g, 8.05 mmol) in THF (5.0 mL) at 0 °C. After stirring at 0 °C for 1 h, a solution of 5 (500 mg, 1.61 mmol) in THF (5.0 mL) was added, and the mixture was stirred at 0 °C for 1 h. The mixture was cooled to -78 °C and a solution of I₂ (2.08 g, 8.21 mmol) in THF (5.0 mL) was added. The mixture was allowed to warm to 0 °C and stirring was continued for 2 h. The reaction was quenched with saturated Na₂S₂O₃ (30 mL) at 0 °C, and the mixture was extracted with AcOEt. The extract was washed with brine, dried, concentrated and chromatographed $(SiO_2 40 \text{ g}, \text{hexane}-\text{AcOEt} = 100:1)$ to give 3 (580 mg, 82%), a yellow oil, as a 6:1 inseparable mixture with its 6-iodoisomer. ¹H NMR δ 7.33–7.21 (m, 1H), 6.22 (br d, J = 13.7 Hz, 1H), 5.89 (d, J = 11.5 Hz, 1H), 4.84 (brs, 1H), 3.66 (s, 3H), 1.80 (s, 3H), 1.22 (s, 3H), 1.11 (s, 3H), 0.87 (s, 9H), 0.04 (s, 3H), -0.05 (s, 3H); ¹³C NMR δ 176.6, 140.6, 133.1, 128.4, 79.0,

74.1, 51.8, 49.3, 25.7, 23.5, 21.8, 18.0, -4.8, -5.4; FTIR (neat) 2952, 1736, 1467, 1256, 1080 cm⁻¹; MS *m/z* 337, 381 (100), 438 (M⁺); HRMS calcd for $C_{17}H_{31}O_3SiI$ (M⁺) 438.1087, found 438.1103.

(R,4Z,6E,8E)-Methyl 3-((tert-butyldimethylsilyl)oxy)-2,2,4-trimethyl-10-(oxazol-5-yl)deca-4,6,8-trienoate (24). Compound 3 containing its 6-iodo-isomer (260 mg, 0.59 mmol) was dissolved in degassed DMF (5.0 mL) and stannane 1^{12c} (260 mg, 0.65 mmol), CuI (11 mg, 0.059 mmol), CsF (180 mg, 1.18 mmol) and Pd(PPh₃)₄ (7 mg, 5.90 µmol) were added at room temperature in the dark. After stirring at room temperature for 3 h, the reaction was guenched with saturated NH₄Cl (10 mL). The mixture was extracted with AcOEt, washed with brine, dried and concentrated. Purification of the residue by flash column chromatography (SiO₂ 20 g, hexane-AcOEt = 15:1 to 7:1) gave 24 (142 mg, 57%) as a yellow oil. $[\alpha]_{D}^{27}$ +117.1 (c 1.41, CHCl₃); ¹H NMR δ 7.79 (s, 1H), 6.80 (s, 1H), 6.44–6.08 (m, 3H), 5.97 (d, J = 11.5 Hz, 1H), 5.73 (td, J = 6.8, 14.9 Hz, 1H), 4.94 (brs, 1H), 3.62 (s, 3H), 3.48 (d, J = 6.8 Hz, 2H), 1.78 (s, 3H), 1.21 (s, 3H), 1.08 (s, 3H), 0.87 (s, 9H), 0.02 (s, 3H), -0.07 (s, 3H); ¹³C NMR δ 177.4, 151.2, 150.7, 138.6, 133.8, 131.8, 129.8, 128.2, 127.3, 122.8, 74.5, 52.0, 50.0, 29.2, 26.0, 22.6, 21.5, 20.1, 18.3, -4.6, -5.3; FTIR (neat) 2952, 2858, 1733, 1467, 1256, 1077 cm⁻¹; MS *m/z* 318 (100), 419 (M^+) ; HRMS calcd for C₂₃H₃₇NO₄Si (M^+) 419.2492, found 419.2487.

(R,4Z,6E,8E)-Methyl 3-hydroxy-2,2,4-trimethyl-10-(oxazol-5yl)deca-4,6,8-trienoate (25). To a solution of 24 (90 mg, 0.21 mmol) in MeCN (4.0 mL) was added HF-pyridine (0.2 mL) at 0 °C. After being stirred at room temperature for 4 h, the mixture was basified with saturated NaHCO₃ (30 mL) at 0 °C and extracted with AcOEt. The extract was washed with brine, dried, concentrated and purified by flash column chromatography (SiO₂ 6.0 g, hexane–AcOEt = 3:1 to 2:1) to give 25 (47.2 mg, 72%) as a yellow oil. $[\alpha]_D^{27}$ +81.9 (c 0.99, CHCl₃); ¹H NMR δ 7.78 (s, 1H), 6.79 (s, 1H), 6.43 (dd, J = 11.5, 14.0 Hz, 1H), 6.22–6.08 (m, 2H), 6.02 (d, J = 11.5 Hz, 1H), 5.75 (td, J = 6.8, 14.0 Hz, 1H), 4.76 (d, J = 4.9 Hz, 1H), 3.71 (s, 3H), 3.47 (d, J = 6.8 Hz, 2H), 3.29 (d, J = 6.0 Hz, 1H), 1.75 (s, 3H), 1.26 (s, 3H), 1.16 (s, 3H); 13 C NMR δ 178.7, 151.1, 150.7, 132.1, 128.8, 128.4, 127.6, 125.3, 124.4, 122.8, 74.9, 52.5, 47.1, 29.3, 24.7, 21.3, 20.0; FTIR (neat) 3430, 3122, 2949, 1726, 1260, 1136 cm⁻¹; MS m/z 102, 204 (100), 305 (M^+) ; HRMS calcd for $C_{17}H_{23}NO_4$ (M⁺) 305.1627, found 305.1624.

(+)-Inthomycin B. In the same manner as described for the synthesis of (+)-inthomycin A from 22, (+)-inthomycin B (35 mg) was obtained as a yellow oil from 25 (77 mg, 0.25 mmol) in 49% yield (4 steps) after purification by preparative TLC (CHCl₃–MeOH = 9 : 1). $[\alpha]_D^{26}$ +46.8 (*c* 1.25, CHCl₃) (lit.^{12*c*} $[\alpha]_D^{22}$ +19.3 (*c* 1.0, CHCl₃)); ¹H NMR δ 7.79 (s, 1H), 6.80 (s, 1H), 6.46 (dd, *J* = 11.5, 14.0 Hz, 1H), 6.28 (brs, 1H), 6.23–6.11 (m, 2H), 6.01 (d, *J* = 11.5 Hz, 1H), 5.74 (td, *J* = 6.8, 14.0 Hz, 1H), 5.55 (brs, 1H), 4.61 (d, *J* = 4.4 Hz, 1H), 3.98 (brs, 1H), 3.48 (d, *J* = 6.8 Hz, 2H), 1.81 (s, 3H), 1.36 (s, 3H), 1.10 (s, 3H); ¹³C NMR δ 181.0, 150.8, 150.4, 137.6, 133.3, 131.9, 130.1, 127.5, 127.4, 122.5, 75.8, 44.7, 28.8, 26.1,

21.7, 19.2; FTIR (neat) 3343, 2933, 1658, 1602, 1511, 1468, 1376, 1110, 1047 cm⁻¹; MS *m*/*z* 69 (100), 204, 290 (M⁺); HRMS calcd for $C_{16}H_{22}N_2O_3$ (M⁺) 290.1630, found 290.1620.

(*E*,2*S*,3*S*)-Methyl 3-hydroxy-2,4-dimethyl-7-(trimethylsilyl)hept-4-en-6-ynoate. β-Lactone 17 (1.59 g, 0.72 mmol) was subjected to methanolysis using NaOMe (4 mg, 0.072 mmol) in MeOH (70 mL) in the same manner as described for the preparation of 18 from 16. Purification by column chromatography (SiO₂ 70 g, hexane–AcOEt = 8 : 1) gave the methyl ester (1.82 g, 100%) as a yellow oil. $[\alpha]_D^{2d}$ -24.0 (*c* 1.03, CHCl₃); ¹H NMR δ 5.73 (s, 1H), 4.49 (brs, 1H), 3.72 (s, 3H), 2.70 (dq, *J* = 3.4, 7.1 Hz, 1H), 2.67 (d, *J* = 3.4 Hz, 1H), 1.86 (s, 3H), 1.09 (d, *J* = 7.1 Hz, 3H), 0.20 (s, 9H); ¹³C NMR δ 176.0, 150.4, 106.6, 102.4, 99.0, 74.5, 52.0, 42.1, 16.3, 10.0, 0.0; FTIR (neat) 3496, 2359, 2135, 1730, 1445, 1253 cm⁻¹; MS *m*/*z* 167 (100), 254 (M⁺); HRMS calcd for C₁₃H₂₂O₃Si (M⁺) 254.1338, found 254.1349.

(*R,E*)-Methyl 3-hydroxy-2,2,4-trimethyl-7-(trimethylsilyl)hept-4en-6-ynoate. The methyl ester (0.98 g, 3.85 mmol) was methylated in the same manner described for the preparation of **19** from **18**. Purification by flash column chromatography (SiO₂ 60 g, CHCl₃-hexane = 4 : 1) gave the corresponding methylated ester (0.82 g, 80%) as a colorless oil. $[\alpha]_D^{24}$ +17.1 (*c* 1.05, CHCl₃); ¹H NMR δ 5.53 (s, 1H), 4.17 (d, *J* = 5.8 Hz, 1H), 3.71 (s, 3H), 3.04 (d, *J* = 5.8 Hz, 1H), 1.86 (s, 3H), 1.21 (s, 3H), 1.16 (s, 3H), 0.19 (s, 9H); ¹³C NMR δ 177.9, 151.1, 109.2, 102.2, 99.7, 80.8, 60.4, 52.1, 46.6, 23.4, 20.6, 16.7, 14.1, 0.0; FTIR (neat) 3501, 2959, 2360, 2135, 1724, 1253 cm⁻¹; MS *m*/*z* 102, 167 (100), 268 (M⁺); HRMS calcd for C₁₄H₂₄O₃Si (M⁺) 268.1494, found 268.1501.

(*R,E*)-Methyl 3-hydroxy-2,2,4-trimethylhept-4-en-6-ynoate (26). The methylated ester (0.57 g, 2.12 mmol) was desilylated under methanolytic conditions using NaOMe (57 mg, 1.06 mmol) in MeOH (20 mL) at 0 °C in the same manner as described for the preparation of 20 from 19. Purification by column chromatography (SiO₂ 20 g, hexane–AcOEt = 6:1) gave 26 (0.42 g, 100%) as a yellow oil. $[\alpha]_{D}^{24}$ –15.9 (*c* 1.04, CHCl₃); ¹H NMR δ 5.51 (s, 1H), 4.19 (d, *J* = 5.8 Hz, 1H), 3.72 (s, 3H), 3.16–3.14 (m, 1H), 1.88 (s, 3H), 1.22 (s, 3H), 1.17 (s, 3H); ¹³C NMR δ 178.1, 152.0, 108.5, 82.6, 81.1, 80.9, 52.5, 46.9, 23.8, 21.0, 16.9; FTIR (neat) 3492, 3291, 2983, 1721, 1443, 1259, 1138, 1073 cm⁻¹; MS *m/z* 102 (100), 196 (M⁺); HRMS calcd for C₁₁H₁₆O₃ (M⁺) 196.1099, found 196.1088.

(*R*,4*E*,6*E*)-Methyl 3-hydroxy-7-iodo-2,2,4-trimethylhepta-4,6dienoate (29). To a solution of CuCN (62 mg, 0.69 mmol) in THF (1.5 mL) was added dropwise *n*-BuLi (2.66 M in hexane, 0.52 mL, 1.39 mmol) at -78 °C. After stirring at -40 °C for 10 min, *n*-Bu₃SnH (0.36 mL, 1.39 mmol) was added dropwise at -78 °C. After stirring at -40 °C for 10 min, a solution of 26 (30 mg, 0.15 mmol) in THF (1.5 mL) was added, and the mixture was allowed to warm to -30 °C. After stirring at -30 °C for 1 h, saturated NH₄Cl (2.5 mL) and NH₄OH (0.5 mL) were added, and the mixture was allowed to warm to -10 °C. After being stirred at -10 °C for 0.5 h, the mixture was extracted

with AcOEt, washed with brine, dried and concentrated to give the alkenylstannane (444 mg). The crude alkenylstannane (444 mg) was dissolved in THF (2.0 mL) and a solution of I₂ (240 mL, 0.94 mmol) in THF (1.0 mL) was added at -78 °C in the dark, and the mixture was stirred at room temperature for 20 h. The reaction was guenched with saturated Na₂S₂O₃ (10 mL), and the mixture was extracted with AcOEt. The extract was washed with brine, dried, concentrated and purified by flash column chromatography (SiO₂ 6.0 g, hexane–AcOEt = 7:1) to give 29 (29 mg, 60%) as a yellow oil. $[\alpha]_D^{23}$ +8.6 (c 1.32, CHCl₃); ¹H NMR δ 7.26 (dd, J = 11.2, 14.3 Hz, 1H), 6.33 (d, J = 14.3 Hz, 1H), 5.94 (d, J = 11.2 Hz, 1H), 4.12 (d, J = 5.5 Hz, 1H), 3.71 (s, 3H), 3.09 (d, J = 5.5 Hz, 1H), 1.70 (s, 3H), 1.21 (s, 3H), 1.15 (s, 3H); ¹³C NMR δ 178.1, 141.1, 137.6, 128.4, 81.7, 80.0, 52.2, 46.7, 23.6, 20.7, 14.2; FTIR (neat) 3491, 2979, 2945, 1726, 1462, 1258, 1138, 1047 cm⁻¹; MS *m/z* 102 (100), 324 (M^+) ; HRMS calcd for $C_{17}H_{17}O_3I$ (M^+) 324.0222, found 324.0222.

(R,4E,6E,8E)-Methyl 3-hydroxy-2,2,4-trimethyl-10-(oxazol-5yl)deca-4,6,8-trienoate (30). To a solution 29 (24 mg, 74 µmol) and oxazole stannane 1^{12c} (32 mg, 81 µmol) in degassed DMF (1.0 mL) were added CuI (1.4 mg, 1.4 µmol), CsF (22 mg, 148 µmol), and Pd(PPh₃)₄ (1 mg, 0.74 µmol) at room temperature in the dark. The reaction mixture was stirred at room temperature for 3 h, quenched with saturated KF (1.0 mL), and extracted with AcOEt. The extract was washed with brine, dried and concentrated. Purification of the residue by flash column chromatography (SiO₂ 6.0 g, hexane–AcOEt = 15:1 to 2:1) gave **30** (18 mg, 79%) as a yellow oil. $[\alpha]_D^{22}$ +0.78 (c 1.39, CHCl₃); ¹H NMR δ 7.79 (s, 1H), 6.80 (s, 1H), 6.43–6.37 (m, 1H), 6.27–6.18 (m, 2H), 6.02 (d, J = 11.0 Hz, 1H), 5.75 (td, J =6.7, 13.8 Hz, 1H), 4.17 (d, J = 5.4 Hz, 1H), 3.71 (s, 3H), 3.49 (d, J = 6.7 Hz, 2H), 3.09 (d, J = 5.4 Hz, 1H), 1.74 (s, 3H), 1.21 (s, 3H), 1.15 (s, 3H); 13 C NMR δ 177.8, 150.5, 150.1, 137.0, 133.1, 131.8, 128.2, 127.8, 127.0, 122.2, 81.8, 51.8, 46.7, 28.5, 23.3, 20.4, 13.6; FTIR (neat) 3383, 3128, 2982, 2949, 1727, 1510, 1463, 1257, 1134 cm⁻¹; MS m/z 102, 204 (100), 305 (M^{+}) ; HRMS calcd for $C_{17}H_{23}NO_4$ (M^{+}) 305.1627, found 305.1624.

(-)-Inthomycin C. In the same manner as described for the synthesis of (+)-inthomycin A from 22, (-)-inthomycin C (19 mg) was obtained as a yellow oil from 30 (117 mg, 0.38 mmol) in 22% yield (4 steps) after purification by preparative TLC (CHCl₃-MeOH = 9 : 1). $[\alpha]_{D}^{23}$ -41.5 (*c* 0.10, CHCl₃) (lit.¹⁴ $[\alpha]_{D}^{20}$ -34.3 (*c* 0.10, CHCl₃)); ¹H NMR δ 7.79 (s, 1H), 6.79 (s, 1H), 6.39 (dd, J = 11.2, 14.2 Hz, 1H), 6.24–6.20 (m, 3H), 6.02 (d, J = 11.2 Hz, 1H), 5.75 (td, J = 6.8, 14.2 Hz, 1H), 5.40 (brs, 1H), 4.01 (d, J = 4.6 Hz, 1H), 3.72 (brs, 1H), 3.48 (d, J = 6.8 Hz, 2H), 1.79 (s, 3H), 1.30 (s, 3H), 1.10 (s, 3H); ¹³C NMR δ 180.6, 150.8, 150.4, 137.8, 133.4, 132.4, 128.8, 127.4, 122.5, 83.8, 45.0, 28.8, 25.7, 21.7, 13.3; FTIR (neat) 3341, 2925, 2849, 1739, 1658, 1510, 1469, 1372, 1103 cm⁻¹; MS *m/z* 87 (100), 204, 290 (M⁺); HRMS calcd for C₁₆H₂₂N₂O₃ (M⁺) 290.1630, found 290.1629.

Acknowledgements

This work was supported by the Grant-in-Aid for Scientific Research (A) (22249001) from JSPS and the Grant-in-Aid for Scientific Research on Innovative Areas "Advanced Molecular Transformations by Organocatalysis" (no. 2304) (24105526) from MEXT.

Notes and references

- (a) T. Mori, K. Takahashi, M. Kashiwabara, D. Uemura, C. Katayama, S. Iwadare, Y. Shizuri, R. Mitomo, F. Nakano and A. Matsuzaki, *Tetrahedron Lett.*, 1985, 26, 1073; (b) K. Takahashi, M. Kawabata, D. Uemura, S. Iwadare, R. Mitomo, F. Nakano and A. Matsuzaki, *Tetrahedron Lett.*, 1985, 26, 1077.
- 2 For a review, see: M. G. Moloney, P. C. Trippier, M. Yaqoob and Z. Wang, *Curr. Drug Discovery Technol.*, 2004, **1**, 181.
- 3 (a) A. S. Kende, K. Kawamura and M. J. Orwat, Tetrahedron Lett., 1989, 30, 5821; (b) M. D. Andrews, A. G. Brewster and M. G. Moloney, Synlett, 1996, 612; (c) J. N. P. Papillon and R. J. Taylor, Org. Lett., 2000, 2, 1987; (d) P. G. Bulger, M. G. Moloney and P. C. Trippier, Synlett, 2002, 1871; (e) Z. Wang and M. G. Moloney, Tetrahedron Lett., 2002, 43, 9629; (f) P. G. Bulger, M. G. Moloney and P. C. Trippier, Org. Biomol. Chem., 2003, 1, 3726; (g) D. K. Mohapatra, D. Mondal, R. G. Gonnade, M. S. Chorghade and M. K. Gurjar, Tetrahedron Lett., 2006, 47, 6031; (h) T. J. Donohoe, J. Y. K. Chiu and R. E. Thomas, Org. Lett., 2007, 9, 421; (i) N. J. Bennett, J. C. Prodger and G. Pattenden, Tetrahedron, 2007, 63, 6216; (j) T. Yamada, K. Sakaguchi, T. Shinada, Y. Ohfune and V. A. Soloshonok, Tetrahedron: Asymmetry, 2008, 19, 2789; (k) C. L. Bagwell, M. G. Moloney and A. L. Thompson, Bioorg. Med. Chem. Lett., 2008, 18, 4081; (1) C. L. Bagwell, M. G. Moloney and M. Yaqoob, Bioorg. Med. Chem. Lett., 2010, 20, 2090; (m) D. Mondal and S. Bera, Synthesis, 2010, 3301.
- 4 A. S. Kende, K. Kawamura and R. J. DeVita, J. Am. Chem. Soc., 1990, 112, 4070.
- 5 (a) E. O. Onyango, J. Tsurumoto, N. Imai, K. Takahashi, J. Ishihara and S. Hatakeyama, *Angew. Chem.*, *Int. Ed.*, 2007, **46**, 6703; (b) S. Hatakeyama, *Pure Appl. Chem.*, 2009, **81**, 217.
- 6 K. Eto, M. Yoshino, K. Takahashi, J. Ishihara and S. Hatakeyama, Org. Lett., 2011, 13, 5398.
- 7 (a) S. Ōmura, Y. Tanaka, I. Kanaya, M. Shinose and Y. Takahashi, J. Antibiot., 1990, 43, 1034; (b) Y. Tanaka, I. Kanaya, K. Shiomi, H. Tanaka and S. Ōmura, J. Antibiot., 1993, 46, 1214.
- 8 T. Henkel and A. Zeeck, Liebigs Ann. Chem., 1991, 367.
- 9 (a) P. A. Grigorjev, R. Schlegel and U. Grafe, *Pharmazie*, 1992, **36**, 707; (b) E. Tonew, M. Tonew, U. Grafe and P. Zopel, *Acta Virol.*, 1992, **36**, 166; (c) C. Toniolo, M. Crisma, F. Formaggio, C. Pegggion, R. F. Epand and R. M. Epand, *Cell. Mol. Life Sci.*, 2001, **58**, 1179.
- 10 (a) Y. Tanaka, I. Kanaya, Y. Takahashi, M. Shinose, H. Tanaka and S. Ōmura, J. Antibiot., 1993, 46, 1208; (b) S. Ōmura, Gene, 1992, 115, 141.
- 11 M. Kawada, Y. Yoshimoto, K. Minamiguchi, H. Kumagai, T. Someno, T. Masuda, M. Ishizuka and D. Ikeda, *Anticancer Res.*, 2004, 24, 1561.
- (a) N. Hénaff and A. Whiting, Org. Lett., 1999, 1, 1137; (b) N. Hénaff and A. Whiting, Tetrahedron, 2000, 56, 5193; (c) M. R. Webb, M. S. Addie, C. M. Crawforth, J. W. Dale, X. Franci, M. Pizzonero, C. Donald and R. J. K. Taylor, Tetrahedron, 2008, 64, 4778.
- 13 M. R. Webb, C. Donald and R. J. K. Taylor, *Tetrahedron Lett.*, 2006, 47, 549.
- 14 B. K. Senapati, L. Gao, S. I. Lee, G.-S. Hwang and D. H. Ryu, Org. Lett., 2010, 12, 5088.
- 15 For reviews, see: (a) H. W. Yang and D. Romo, *Tetrahedron*, 1999, 55, 6403; (b) Y. Wang, R. L. Tennyson and D. Romo, *Heterocycles*, 2004, 64, 605.
- 16 (a) G. S. Cortez, S. H. Oh and D. Romo, *Synthesis*, 2001, 1731; (b) G. S. Cortez, R. L. Tennyson and D. Romo, *J. Am. Chem. Soc.*, 2001, 123, 7945.
- 17 J. E. Wilson and G. C. Fu, Angew. Chem., Int. Ed., 2004, 43, 6358.
- 18 (a) S. G. Nelson and Z. Wan, Org. Lett., 2000, 2, 1883; (b) S. G. Nelson, C. Zhu and X. Shen, J. Am. Chem. Soc., 2004, 126, 14; (c) C. Zhu, X. Shen and S. G. Nelson, J. Am. Chem. Soc., 2004, 126, 5352.

- 19 Z. Tan and E. Negishi, Org. Lett., 2006, 8, 2783.
- 20 D. Seebach, D. Aebiand and D. Wasmuth, Org. Synth., 1985, 63, 109.
- 21 S. P. H. Mee, V. Lee and J. E. Baldwin, Chem.-Eur. J., 2005, 11, 3294.
- 22 (a) Z. Haung and E. Negishi, Org. Lett., 2006, **8**, 3675; (b) B. H. Lipshutz and B. Amorelli, J. Am. Chem. Soc., 2009, **131**, 1396;

(c) T. Magauer, H. J. Martin and J. Mulzer, *Angew. Chem., Int. Ed.*, 2009, **48**, 6032.

- 23 (a) J. F. Betzer, F. Delaloge, B. Muller, A. Pancrazi and J. Prunet, J. Org. Chem., 1997, 62, 7768; (b) A. Darwish, A. Lang, T. Kim and J. M. Chong, Org. Lett., 2008, 10, 861.
- 24 (a) F. Effenberger and M. Wezstein, *Synthesis*, 2001, 1368; (b) S. E. Denmark and W. Pan, *Org. Lett.*, 2001, **3**, 61.